-
Innovation Ranking
Innovation Ranking – GeoVax Labs Inc
GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Salivary Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Salivary Gland Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Salivary Gland Cancer Drug Details: Gedeptin (Ad/PNP-F-araAMP) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Nasopharyngeal Cancer Drug Details: Gedeptin (Ad/PNP-F-araAMP) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNC-102 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNC-102 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNC-102 in Relapsed Multiple Myeloma Drug Details: SNC-102 is under development...
-
Product Insights
NewEbolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain, and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids, and pain relievers. The Ebolavirus Infections (Ebola Hemorrhagic Fever) drugs in development market...
-
Product Insights
NewLassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes, and bleeding. The antiviral drug ribavirin seems to be an effective...
-
Product Insights
NewMonkeypox – Drugs In Development, 2024
Empower your strategies with our Monkeypox – Drugs In Development, 2024 report and make more profitable business decisions. Mpox, caused by the monkeypox virus, is an infectious disease presenting with a painful rash, fever, and enlarged lymph nodes. While most individuals fully recover, some may experience severe illness. Person-to-person transmission occurs through direct contact with infectious skin or lesions, including those in the mouth or genitals. Symptoms manifest from 1-21 days after exposure, lasting 2-4 weeks or longer in individuals with...
-
Product Insights
NewHuman Papillomavirus Infections – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Human Papillomavirus (HPV) infections are common sexually transmitted infections caused by the HPV virus. There exist over 100 types, some leading to genital warts, while others increase the risk of various cancers, including cervical, anal, and throat cancers. Often asymptomatic, HPV can spread through sexual contact, including skin-to-skin contact. Vaccines effectively prevent many high-risk HPV types, reducing infection and cancer risk....
-
Product Insights
NewZika Virus Infections – Drugs In Development, 2024
Empower your strategies with our Zika Virus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain...